BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

767 related articles for article (PubMed ID: 34387604)

  • 21. Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma.
    Tisi MC; Cupelli E; Santangelo R; Maiolo E; Alma E; Giachelia M; Martini M; Bellesi S; D'Alò F; Voso MT; Pompili M; Leone G; Larocca LM; Hohaus S
    Leuk Lymphoma; 2016; 57(3):628-34. PubMed ID: 26458141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Analysis of Factors Influencing Clinical Efficacy of Rituximab on Patients with Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma].
    Zhong M; Su QH; Xu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1210-1214. PubMed ID: 32798400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru.
    Beltran BE; Castillo JJ; Morales D; de Mendoza FH; Quinones P; Miranda RN; Gallo A; Lopez-Ilasaca M; Butera JN; Sotomayor EM
    Am J Hematol; 2011 Aug; 86(8):663-7. PubMed ID: 21761432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
    Hong JY; Ryu KJ; Park C; Hong M; Ko YH; Kim WS; Kim SJ
    Oncotarget; 2017 Feb; 8(8):13782-13791. PubMed ID: 28099151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro.
    Quan L; Chen X; Liu A; Zhang Y; Guo X; Yan S; Liu Y
    PLoS One; 2015; 10(9):e0136476. PubMed ID: 26361042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary bilateral adrenal lymphoma revealed by hemophagocytic syndrome.
    Alaoua A; Gilbert G; Ghannouchi N; Houchlef M; Letaief A; Bahri F
    Ann Endocrinol (Paris); 2011 Jun; 72(3):247-50. PubMed ID: 21640976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful treatment of hemophagocytic syndrome in a patient with T cell lymphoma, EBV infection, and bone marrow necrosis: A case report.
    Xu L; Liu X; Wang Y; Wang Y; Chu X; Chen L
    Medicine (Baltimore); 2022 Mar; 101(9):e28943. PubMed ID: 35244052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcome of elderly patients with Epstein-Barr virus positive diffuse large B-cell lymphoma treated with a combination of rituximab and CHOP chemotherapy.
    Ahn JS; Yang DH; Duk Choi Y; Jung SH; Yhim HY; Kwak JY; Sung Park H; Shin MG; Kim YK; Kim HJ; Lee JJ
    Am J Hematol; 2013 Sep; 88(9):774-9. PubMed ID: 23760676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
    Dunleavy K; Fanale MA; Abramson JS; Noy A; Caimi PF; Pittaluga S; Parekh S; Lacasce A; Hayslip JW; Jagadeesh D; Nagpal S; Lechowicz MJ; Gaur R; Lucas A; Melani C; Roschewski M; Steinberg SM; Jaffe ES; Kahl B; Friedberg JW; Little RF; Bartlett NL; Wilson WH
    Lancet Haematol; 2018 Dec; 5(12):e609-e617. PubMed ID: 30501868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
    Pejša V; Prka Ž; Lucijanić M; Mitrović Z; Piršić M; Jakšić O; Ajduković R; Kušec R
    Croat Med J; 2017 Feb; 58(1):40-48. PubMed ID: 28252874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
    Purroy N; Bergua J; Gallur L; Prieto J; Lopez LA; Sancho JM; García-Marco JA; Castellví J; Montes-Moreno S; Batlle A; de Villambrosia SG; Carnicero F; Ferrando-Lamana L; Piris MA; Lopez A
    Br J Haematol; 2015 Apr; 169(2):188-98. PubMed ID: 25521006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapeutic developments and advances in B-cell lymphoma].
    Miyazaki K
    Rinsho Ketsueki; 2022; 63(6):619-625. PubMed ID: 35831197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution.
    Huang JJ; Xia Y; Wang Y; Liu PP; Bi XW; Sun P; Lin TY; Jiang WQ; Li ZM
    Oncotarget; 2016 Jul; 7(27):41242-41250. PubMed ID: 27183909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence and clinicopathologic features of CD30-positive de novo diffuse large B-cell lymphoma in Chinese patients: a retrospective study of 232 cases.
    Gong QX; Lu TX; Liu C; Wang Z; Liang JH; Xu W; Li JY; Zhang ZH; Chen Q
    Int J Clin Exp Pathol; 2015; 8(12):15825-35. PubMed ID: 26884853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Composite B-cell and T-cell lymphomas: clinical, pathological, and molecular features of three cases and literature review.
    Jin X; Liu H; Li J; Xiao X; Yuan X; Chen P; Chen B; Liang Y; Huang F
    J Zhejiang Univ Sci B; 2023 Aug; 24(8):711-722. PubMed ID: 37551557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [EBV-positive diffuse large B-cell lymphoma in young individual: report of a case].
    Li WS; Xie JL; Zhang M; Zhou XG
    Zhonghua Bing Li Xue Za Zhi; 2013 Feb; 42(2):128-9. PubMed ID: 23710923
    [No Abstract]   [Full Text] [Related]  

  • 38. Diffuse large B-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma.
    Skugor ND; Perić Z; Vrhovac R; Radić-Kristo D; Kardum-Skelin I; Jaksić B
    Coll Antropol; 2010 Mar; 34(1):241-5. PubMed ID: 20432757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A case report of a renal diffuse B-cell lymphoma.
    Patel RD; Walker C; Canter DJ
    Can J Urol; 2017 Feb; 24(1):8670-8672. PubMed ID: 28263135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential development of peripheral t-cell lymphoma post immunochemotherapy of diffuse large B cell lymphoma.
    Wang JW; Chen JY; Lu C; Tang X
    Cancer Biol Ther; 2017 Apr; 18(4):201-202. PubMed ID: 28278073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.